PreprintPreprintNov 2026
Murugadoss K, Venkatakrishnan A, Soundararajan V.
Semaglutide lowers cardiovascular events in adults with obesity, but whether it slows biological aging of the heart, and whether any such effect is explained by weight loss, is unknown. We developed and validated a hybrid convolutional and transformer deep lea...
StudyGeroScienceNov 2026
Ditchfield C, Macleod M, Price JMJ, Davis ET, Jones SW.
GLP-1 and GIP/GLP-1 receptor agonists produce substantial weight loss in clinical trials but significant loss of lean body mass is reported. Whether this reflects a direct pharmacological effect on skeletal muscle or an indirect consequence of caloric restrict...
PreprintPreprintNov 2026
Borkowski AA.
Artificial intelligence (AI) has expanded the scale, resolution, and modalities through which biological aging can be estimated, but evidence that these estimates are valid intervention targets or surrogate endpoints remains limited. We conducted a narrative r...
StudyHerzNov 2026
Kafka A, Becker L, Hauner H, Wackerhage H.
Age is the strongest risk factor for cardiovascular disease, yet biological aging is increasingly recognized as a modifiable process. Animal studies over the past few decades have demonstrated that genetic, pharmacological, and dietary interventions can extend...
StudyJournal of Alzheimer's disease : JADOct 2026
Kamihara T, Kato R, Morisaki A, Kaneko S, Omura T, Shimizu A.
BackgroundAlzheimer's disease (AD) currently lacks fundamental curative treatments. While epidemiological evidence increasingly links sodium-glucose cotransporter 2 (SGLT2) inhibitors to reduced AD risk, the underlying molecular mechanisms remain poorly unders...
StudyEndocrineOct 2026
Jain V, McCoy RG.
Purpose Sodium-glucose cotransporter-2 inhibitors (SGLT2i) carry Class I, Level A recommendations for type 2 diabetes (T2D), heart failure (HF), and chronic kidney disease (CKD) but remain underused outside T2D, with formulary restrictions commonly cited as a ...